NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
33.3%
尚未招募
1
33.3%
终止
1
33.3%
暂无批准数据
- NervGen Pharma appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy and Clinical Affairs to advance their spinal cord injury treatment program. - Ruff brings over 30 years of regulatory expertise from companies including Stoke Therapeutics and Sarepta Therapeutics to guide NVG-291 toward potential approval as the first pharmacologic treatment for SCI. - McSherry, who founded the Jett Foundation after her son's Duchenne muscular dystrophy diagnosis, will ensure the SCI community's voice remains central to NervGen's clinical strategy. - The appointments strengthen NervGen's leadership as the company prepares for Phase 3 trials of NVG-291, which demonstrated durable improvements in function and quality of life in chronic SCI patients.
• NervGen Pharma will host a virtual investor event on April 9, 2025, featuring key opinion leaders to discuss the unmet medical needs and treatment landscape for spinal cord injury patients. • The company will present details of its Phase 1b/2a clinical trial evaluating NVG-291, a first-in-class therapeutic peptide targeting nervous system repair in both chronic and subacute spinal cord injury patients. • Clinical data from the double-blind, randomized, placebo-controlled trial is expected in the second quarter, with the study measuring corticospinal connectivity changes and motor function improvements as primary endpoints.
• The spinal cord injury (SCI) market is projected to grow significantly, driven by increasing prevalence and advancements in treatment options. • Emerging therapies like KP-100IT, Neuro-Cells, and MT-3921 are expected to transform the SCI treatment landscape, offering new standards of care. • Clinical trials are underway for several promising SCI treatments, including NervGen Pharma's NVG-291 and Mitsubishi Tanabe Pharma's MT-3921. • The SCI market in the 7MM is estimated to increase from USD 345 million in 2023 to a CAGR of 15.4% by 2034, according to DelveInsight.
• Spinal Cord Injury (SCI) pipeline includes 35+ therapies from companies like Athersys and NervGen Pharma, targeting mechanisms from stem cell therapy to neuroprotection. • Ankylosing Spondylitis (AS) pipeline features 20+ therapies, with companies like UCB Biopharma and MoonLake Immunotherapeutics developing treatments such as bimekizumab and sonelokimab. • Clinical trials for SCI include Neuroplast's Phase II trial of Neuro-Cells® showing promising safety, while NeuroSolv Therapeutics seeks investment for Perineline™ to address SCI. • Recent data presented by UCB Biopharma at ACR 2024 highlights sustained improvements in AS with bimekizumab, and AbbVie's RINVOQ is prescribed for adults with active AS.
• NervGen Pharma's CMO, Dr. Daniel Mikol, will present at the U2FP Symposium, addressing challenges in translating SCI animal model results to human clinical trials. • NVG-291, NervGen's therapeutic peptide, targets nervous system repair mechanisms and has shown promise in preclinical models of spinal cord injury. • A Phase 1b/2a trial (NCT05965700) is underway to evaluate NVG-291's efficacy in chronic and subacute cervical spinal cord injury, focusing on motor function improvements. • The trial assesses corticospinal connectivity changes using electrophysiological and MRI imaging, with funding support from Wings for Life.
